Abemaciclib is an oral targeted anticancer drug belonging to the CDK4/6 inhibitor class. It is mainly used for the treatment of hormone receptor‑positive (HR+), human epidermal growth factor receptor 2‑negative (HER2‑) advanced or metastatic breast cancer.
It blocks cancer cell proliferation by inhibiting cyclin‑dependent kinases 4 and 6 (CDK4/6) and is often combined with endocrine therapy (such as fulvestrant or aromatase inhibitors) to prolong progression‑free survival.
Drug Overview
Abemaciclib is a small‑molecule targeted agent that acts through selective inhibition of CDK4/6 protein kinase activity.
These kinases regulate the cell cycle transition from G1 to S phase, and their inhibition prevents cancer cell division. In 2017, the U.S. FDA approved abemaciclib for HR+/HER2‑ advanced breast cancer, with subsequent expansion to adjuvant therapy for high‑risk early breast cancer.
Mechanism of Action
Targeting the CDK4/6 Pathway
When CDK4/6 binds to cyclin D, they phosphorylate the retinoblastoma protein (Rb), releasing the transcription factor E2F and driving cells into the S phase. Abemaciclib blocks this process, arresting cancer cells in the G1 phase and inhibiting proliferation.
Synergistic Combination Therapy
When combined with endocrine agents, abemaciclib can overcome resistance to monotherapy and synergistically suppress tumor growth.
Indicated Patient Populations
Advanced or Metastatic Breast Cancer
Indicated for patients with HR+/HER2‑ disease, especially those with resistance or progression on endocrine therapy.
Adjuvant Therapy for High‑Risk Early Breast Cancer
Used in patients at high risk of postoperative recurrence to reduce the likelihood of relapse.The treatment regimen should be comprehensively evaluated based on genetic testing, pathological subtype, and prior treatment history.
